Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID M WATERHOUSE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578557864
CMS profile
252415
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$153,208.15

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID M WATERHOUSE

NPI 1578557864 · CMS profile ID 252415

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID M WATERHOUSE, NPI 1578557864, CMS profile ID 252415. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID M WATERHOUSE, NPI 1578557864, CMS profile ID 252415. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID M WATERHOUSE, NPI 1578557864, CMS profile ID 252415, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578557864?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $153,208.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $13.5008/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403389 CMS
E.R. Squibb & Sons, L.L.C. $8.0007/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567333 CMS
E.R. Squibb & Sons, L.L.C. $13.4407/30/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567339 CMS
EMD Serono, Inc. $1,380.0007/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849178345 CMS
E.R. Squibb & Sons, L.L.C. $400.0007/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567327 CMS
E.R. Squibb & Sons, L.L.C. $5,300.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567337 CMS
EMD Serono, Inc. $690.0007/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849149359 CMS
GENZYME CORPORATION $2,108.0007/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843762031 CMS
Novartis Pharmaceuticals Corporation $1,965.0007/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813352585 CMS
E.R. Squibb & Sons, L.L.C. $400.0007/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567319 CMS
Janssen Biotech, Inc. $1,200.0007/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403363 CMS
Janssen Biotech, Inc. $5,000.0007/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403371 CMS
Novartis Pharmaceuticals Corporation $16.5907/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813352589 CMS
E.R. Squibb & Sons, L.L.C. $121.0707/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567335 CMS
Regeneron Healthcare Solutions, Inc. $2,292.5007/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809634765 CMS
E.R. Squibb & Sons, L.L.C. $600.0007/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567379 CMS
Janssen Biotech, Inc. $110.8107/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403367 CMS
Janssen Biotech, Inc. $1,004.8507/07/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403369 CMS
Merck Sharp & Dohme Corporation $3,355.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848439321 CMS
Janssen Biotech, Inc. $600.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403361 CMS
Janssen Biotech, Inc. $42.8006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403395 CMS
Amgen Inc. $974.2506/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826323179 CMS
Merck Sharp & Dohme Corporation $3,355.0006/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848592201 CMS
E.R. Squibb & Sons, L.L.C. $1,650.0006/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567321 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845880757 CMS
E.R. Squibb & Sons, L.L.C. $1,500.0005/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567291 CMS
EMD Serono, Inc. $690.0005/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849180707 CMS
JAZZ PHARMACEUTICALS INC. $5,500.0005/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602717 CMS
Janssen Biotech, Inc. $14.6405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403393 CMS
Janssen Biotech, Inc. $1,200.0005/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403365 CMS
E.R. Squibb & Sons, L.L.C. $800.0004/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567279 CMS
Myovant Sciences Inc. $94.5704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834995719 CMS
AstraZeneca Pharmaceuticals LP $92.4804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829520863 CMS
Janssen Biotech, Inc. $1,200.0004/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403359 CMS
Astellas Pharma US Inc $17.9404/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821593981 CMS
Merck Sharp & Dohme Corporation $2,125.0004/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848426261 CMS
Eisai Inc. $1,350.0003/23/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833766427 CMS
Amgen Inc. $1,947.0003/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826530057 CMS
Janssen Biotech, Inc. $1,200.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403353 CMS
Janssen Biotech, Inc. $1,200.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403355 CMS
Janssen Biotech, Inc. $1,200.0003/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403357 CMS
Janssen Biotech, Inc. $1,860.0003/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788403351 CMS
AstraZeneca Pharmaceuticals LP $19.0402/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830017211 CMS
E.R. Squibb & Sons, L.L.C. $300.0002/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567391 CMS
Epizyme, Inc., $11.5002/18/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832343427 CMS
Amgen Inc. $1,947.0002/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826530053 CMS
Amgen Inc. $1,947.0002/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826530055 CMS
E.R. Squibb & Sons, L.L.C. $200.0002/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567125 CMS
E.R. Squibb & Sons, L.L.C. $2,635.0002/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783567259 CMS
Eisai Inc. $1,620.0002/02/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833762743 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $82,403.93 76
PY2020 $103,841.77 85
PY2021 $153,208.15 102
PY2022 $210,495.29 161
PY2023 $262,193.14 241
PY2024 $205,537.47 243
PY2025 $247,135.18 283

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $750.45 2
PY2025 Principal investigator $427,190.23 217
PY2024 Recipient $5,775.77 2
PY2024 Principal investigator $163,925.81 53
PY2023 Principal investigator $333,707.07 39
PY2022 Principal investigator $393,722.48 177
PY2021 Principal investigator $1,407,800.94 307
PY2020 Recipient $72.50 1
PY2020 Principal investigator $668,163.27 598
PY2019 Recipient $162,224.72 20
PY2019 Principal investigator $1,074,939.27 744

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

219 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $425.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754166
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184279392
Principal investigator 1 PFIZER INC. $250.00 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726584
Principal investigator 1 PFIZER INC. $50.00 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726900
Principal investigator 1 PFIZER INC. $1,432.00 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228727109
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753462
Principal investigator 1 PFIZER INC. $250.00 11/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726656
Principal investigator 1 PFIZER INC. $281.00 11/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228727413
Principal investigator 1 PFIZER INC. $1,432.00 11/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228727843
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $425.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753238
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257971
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253827
Principal investigator 1 Amgen Inc. $27,670.00 10/24/2025 Non-covered Recipient Entity
US ONC RESEARCH LLC
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C No dispute reported 06/30/2026 1246651011
Principal investigator 1 PFIZER INC. $125.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228716371
Principal investigator 1 PFIZER INC. $200.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228716551
Principal investigator 1 PFIZER INC. $1,259.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228716553
Principal investigator 1 PFIZER INC. $1,432.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228723390
Principal investigator 1 PFIZER INC. $250.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228724518
Principal investigator 1 PFIZER INC. $1,432.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726941
Principal investigator 1 PFIZER INC. $250.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726943
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228727271
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753950
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 09/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753938
Principal investigator 1 PFIZER INC. $125.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228723058
Principal investigator 1 PFIZER INC. $518.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228724592
Principal investigator 1 PFIZER INC. $2,200.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745351
Principal investigator 1 PFIZER INC. $330.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745445
Principal investigator 1 PFIZER INC. $3,053.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745918
Principal investigator 1 PFIZER INC. $250.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745942
Principal investigator 1 PFIZER INC. $896.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746075
Principal investigator 1 PFIZER INC. $330.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746138
Principal investigator 1 PFIZER INC. $2,042.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746574
Principal investigator 1 PFIZER INC. $150.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228747248
Principal investigator 1 PFIZER INC. $50.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747587
Principal investigator 1 PFIZER INC. $281.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228748077
Principal investigator 1 PFIZER INC. $150.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228748206
Principal investigator 1 PFIZER INC. $1,760.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228749628
Principal investigator 1 PFIZER INC. $250.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749775
Principal investigator 1 PFIZER INC. $2,147.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750422
Principal investigator 1 PFIZER INC. $1,432.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750692
Principal investigator 1 PFIZER INC. $330.00 09/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228751007
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228757385
Principal investigator 1 PFIZER INC. $330.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228758878
Principal investigator 1 PFIZER INC. $235.20 09/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228749237
Principal investigator 1 PFIZER INC. $388.00 08/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228765799
Principal investigator 1 PFIZER INC. $609.00 08/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228784850
Principal investigator 1 PFIZER INC. $3,956.06 08/18/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228766101
Principal investigator 1 PFIZER INC. $1,432.00 08/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228720261
Principal investigator 1 PFIZER INC. $1,432.00 08/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745017
Principal investigator 1 PFIZER INC. $1,760.00 08/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745215
Principal investigator 1 PFIZER INC. $125.00 08/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745824
Principal investigator 1 PFIZER INC. $250.00 08/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749950
Principal investigator 1 PFIZER INC. $250.00 08/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750080
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 08/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228487
Principal investigator 1 PFIZER INC. $388.00 07/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228771563
Principal investigator 1 PFIZER INC. $388.00 07/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228772846
Principal investigator 1 PFIZER INC. $2,555.00 07/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228786183
Principal investigator 1 PFIZER INC. $3,590.00 07/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228787115
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753452
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228722506
Principal investigator 1 PFIZER INC. $1,760.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745719
Principal investigator 1 PFIZER INC. $250.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745786
Principal investigator 1 PFIZER INC. $281.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747583
Principal investigator 1 PFIZER INC. $1,432.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750558
Principal investigator 1 PFIZER INC. $125.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228750736
Principal investigator 1 PFIZER INC. $200.00 07/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228751013
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 07/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184213083
Principal investigator 1 PFIZER INC. $5,934.09 06/16/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228776871
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753234
Principal investigator 1 PFIZER INC. $250.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745302
Principal investigator 1 PFIZER INC. $1,432.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745623
Principal investigator 1 PFIZER INC. $250.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745914
Principal investigator 1 PFIZER INC. $2,200.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745946
Principal investigator 1 PFIZER INC. $330.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745997
Principal investigator 1 PFIZER INC. $330.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746067
Principal investigator 1 PFIZER INC. $2,147.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746178
Principal investigator 1 PFIZER INC. $3,053.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746350
Principal investigator 1 PFIZER INC. $330.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746857
Principal investigator 1 PFIZER INC. $2,042.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747707
Principal investigator 1 PFIZER INC. $1,760.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228750115
Principal investigator 1 PFIZER INC. $1,432.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750120
Principal investigator 1 PFIZER INC. $125.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228750695
Principal investigator 1 PFIZER INC. $518.00 06/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750728
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 06/12/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184206597
Principal investigator 1 PFIZER INC. $388.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228764179
Principal investigator 1 PFIZER INC. $609.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228764685
Principal investigator 1 PFIZER INC. $2,525.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228766045
Principal investigator 1 PFIZER INC. $388.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228771663
Principal investigator 1 PFIZER INC. $3,590.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228772288
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228777528
Principal investigator 1 PFIZER INC. $388.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228782671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184199049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,000.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184199051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,000.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184199053
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 05/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197769
Principal investigator 1 PFIZER INC. $5,869.80 05/19/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
MULTIPLE PART CLINICAL TRIAL OF BRENTUXIMAB VEDOTIN IN CLASSICAL HODGKIN LYMPHOMA SUBJECTS No dispute reported 06/30/2026 1228773052
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $1,890.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753094
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753096
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $425.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754058
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $81.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754060
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $675.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754062
Recipient Amgen Inc. $43.33 05/15/2025 Covered Recipient Physician Real world US NSCLC standard of care No dispute reported 06/30/2026 1246637050
Principal investigator 1 PFIZER INC. $1,432.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745024
Principal investigator 1 PFIZER INC. $250.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745218
Principal investigator 1 PFIZER INC. $1,760.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745270
Principal investigator 1 PFIZER INC. $125.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745621
Principal investigator 1 PFIZER INC. $200.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745766
Principal investigator 1 PFIZER INC. $1,760.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745990
Principal investigator 1 PFIZER INC. $1,600.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228746182
Principal investigator 1 PFIZER INC. $125.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228746693
Principal investigator 1 PFIZER INC. $281.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747241
Principal investigator 1 PFIZER INC. $1,600.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228747863
Principal investigator 1 PFIZER INC. $62.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228748470
Principal investigator 1 PFIZER INC. $57.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228749813
Principal investigator 1 PFIZER INC. $1,600.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228749817
Principal investigator 1 PFIZER INC. $1,600.00 05/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228751159
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,200.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184193853
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184193855
Principal investigator 1 Amgen Inc. $44,143.00 04/24/2025 Non-covered Recipient Entity
US ONC RESEARCH LLC
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246651024
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 04/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754064
Principal investigator 1 PFIZER INC. $2,147.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745020
Principal investigator 1 PFIZER INC. $330.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745348
Principal investigator 1 PFIZER INC. $330.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745354
Principal investigator 1 PFIZER INC. $1,432.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745911
Principal investigator 1 PFIZER INC. $3,053.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746637
Principal investigator 1 PFIZER INC. $250.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746852
Principal investigator 1 PFIZER INC. $400.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228746969
Principal investigator 1 PFIZER INC. $1,760.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228747073
Principal investigator 1 PFIZER INC. $250.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747245
Principal investigator 1 PFIZER INC. $2,200.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747457
Principal investigator 1 PFIZER INC. $1,432.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747461
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228748081
Principal investigator 1 PFIZER INC. $518.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750733
Principal investigator 1 PFIZER INC. $125.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228750841
Principal investigator 1 PFIZER INC. $330.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750843
Principal investigator 1 PFIZER INC. $2,042.00 04/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750890
Principal investigator 1 PFIZER INC. $588.00 04/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228779311
Principal investigator 1 PFIZER INC. $388.00 04/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228779681
Principal investigator 1 PFIZER INC. $388.00 04/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228781274
Principal investigator 1 PFIZER INC. $388.00 04/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228795845
Principal investigator 1 PFIZER INC. $2,555.00 04/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228800513
Recipient Amgen Inc. $707.12 03/27/2025 Covered Recipient Physician MAIC sotorasib vs adagrasib 2L+ NSCLC No dispute reported 06/30/2026 1246637048
Principal investigator 1 PFIZER INC. $5,934.09 03/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228795915
Principal investigator 1 PFIZER INC. $1,881.60 03/17/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228724642
Principal investigator 1 PFIZER INC. $2,200.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228720413
Principal investigator 1 PFIZER INC. $140.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228720645
Principal investigator 1 PFIZER INC. $1,760.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228744559
Principal investigator 1 PFIZER INC. $1,497.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744563
Principal investigator 1 PFIZER INC. $2,147.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745583
Principal investigator 1 PFIZER INC. $330.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745585
Principal investigator 1 PFIZER INC. $140.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745590
Principal investigator 1 PFIZER INC. $2,042.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745680
Principal investigator 1 PFIZER INC. $281.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746079
Principal investigator 1 PFIZER INC. $150.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746084
Principal investigator 1 PFIZER INC. $250.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746088
Principal investigator 1 PFIZER INC. $330.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746300
Principal investigator 1 PFIZER INC. $330.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746305
Principal investigator 1 PFIZER INC. $40.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746309
Principal investigator 1 PFIZER INC. $40.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746860
Principal investigator 1 PFIZER INC. $250.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746974
Principal investigator 1 PFIZER INC. $50.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747028
Principal investigator 1 PFIZER INC. $896.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747138
Principal investigator 1 PFIZER INC. $250.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747146
Principal investigator 1 PFIZER INC. $40.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747704
Principal investigator 1 PFIZER INC. $125.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228748212
Principal investigator 1 PFIZER INC. $40.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749624
Principal investigator 1 PFIZER INC. $1,432.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750837
Principal investigator 1 PFIZER INC. $500.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228751166
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754204
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,100.00 03/03/2025 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC) No dispute reported 06/30/2026 1235992155
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228719373
Principal investigator 1 PFIZER INC. $200.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228724234
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745298
Principal investigator 1 PFIZER INC. $1,760.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745442
Principal investigator 1 PFIZER INC. $2,147.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745548
Principal investigator 1 PFIZER INC. $125.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745684
Principal investigator 1 PFIZER INC. $125.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745738
Principal investigator 1 PFIZER INC. $1,432.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745770
Principal investigator 1 PFIZER INC. $1,600.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745820
Principal investigator 1 PFIZER INC. $3,053.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745950
Principal investigator 1 PFIZER INC. $1,760.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228746071
Principal investigator 1 PFIZER INC. $1,600.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228746569
Principal investigator 1 PFIZER INC. $2,042.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746633
Principal investigator 1 PFIZER INC. $250.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747033
Principal investigator 1 PFIZER INC. $518.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747700
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749953
Principal investigator 1 PFIZER INC. $2,200.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750124
Principal investigator 1 PFIZER INC. $20.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750383
Principal investigator 1 PFIZER INC. $1,432.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750389
Principal investigator 1 PFIZER INC. $1,600.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228751017
Principal investigator 1 PFIZER INC. $250.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228751480
Principal investigator 1 PFIZER INC. $1,600.00 02/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228751484
Principal investigator 1 PFIZER INC. $10,446.45 02/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228800046
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 01/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753534
Principal investigator 1 Amgen Inc. $19,132.90 01/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INCORPORATED
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246645954
Principal investigator 1 Amgen Inc. $28,147.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A Non-interventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1246645968
Principal investigator 1 Amgen Inc. $30,742.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) No dispute reported 06/30/2026 1246645979
Principal investigator 1 Amgen Inc. $116.69 01/15/2025 Non-covered Recipient Entity
ONCOLOGY/ HEMATOLOGY CARE, INC.
MyLung Consortium Study (USOR) No dispute reported 06/30/2026 1246645999
Principal investigator 1 AstraZeneca Pharmaceuticals LP $160.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY ASSOC
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185552495
Principal investigator 1 Eli Lilly and Company $133.35 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC
Not supplied No dispute reported 06/30/2026 1187888470
Principal investigator 1 PFIZER INC. $900.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745262
Principal investigator 1 PFIZER INC. $500.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745266
Principal investigator 1 PFIZER INC. $125.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228745617
Principal investigator 1 PFIZER INC. $281.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745689
Principal investigator 1 PFIZER INC. $900.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745994
Principal investigator 1 PFIZER INC. $1,432.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746579
Principal investigator 1 PFIZER INC. $1,977.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746978
Principal investigator 1 PFIZER INC. $281.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747142
Principal investigator 1 PFIZER INC. $1,760.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES No dispute reported 06/30/2026 1228747966
Principal investigator 1 PFIZER INC. $250.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228748085
Principal investigator 1 PFIZER INC. $1,642.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749782
Principal investigator 1 PFIZER INC. $250.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749808
Principal investigator 1 PFIZER INC. $250.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750380
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228750699
Principal investigator 1 PFIZER INC. $250.00 01/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228751162
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753212